GENTAK ® Gentamicin Sulfate Ophthalmic Ointment USP, 0.3% Sterile

Manufacturer
Akorn | Akorn Operating Company LLC
Effective date
2022-01-28
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
5
Source
legacy-cache
Hydrated at
2026-08-01 22:11:01

Label at a glance#

ProductGentak
Active ingredientGentamicin Sulfate
Label structure12 sections

Indications and uses

Gentamicin sulfate ophthalmic ointment is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharonconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms:   Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus p...

Dosage and administration

Apply a small amount (approximately 1/2 inch ribbon) of ointment to the affected eye(s) two or three times a day.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION

DESCRIPTION SECTION

GENTAK® Gentamicin sulfate is a water soluble antibiotic of the aminoglycoside group.

Gentamicin sulfate ophthalmic ointment is a sterile ointment for ophthalmic use. Each gram contains gentamicin sulfate equivalent to 3 mg gentamicin in a base of white petrolatum and mineral oil, with methylparaben and propylparaben as preservatives.

Gentamicin is obtained from cultures of Micromonospora purpurea. It is a mixture of the sulfate salts of gentamicin C1, C2, and C1A. All three components appear to have similar antimicrobial activities. Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol. The structural formula is as follows:

Structural Formula
Structural Formula

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

MICROBIOLOGY SECTION

Microbiology: Gentamicin sulfate is active in vitro against many strains of the following microorganisms:

  • Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Gentamicin sulfate ophthalmic ointment is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharonconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms:

  • Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Gentamicin sulfate ophthalmic ointment is contraindicated in patients with known hypersensitivity to any of the components.

WARNINGS

WARNINGS SECTION

NOT FOR INJECTION INTO THE EYE.

Gentamicin sulfate ophthalmic ointment is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

PRECAUTIONS

PRECAUTIONS SECTION

GENERAL PRECAUTIONS SECTION

General: Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible organisms including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.

If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted.

Ophthalmic ointments may retard corneal healing.

INFORMATION FOR PATIENTS SECTION

Information for patients: To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis, Mutagenesis, Impairment of Fertility: There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

PREGNANCY SECTION

Pregnancy: Pregnancy Category C. Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

PEDIATRIC USE SECTION

Pediatric Use: Safety and effectiveness in neonates have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia.

Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Apply a small amount (approximately 1/2 inch ribbon) of ointment to the affected eye(s) two or three times a day.

HOW SUPPLIED

HOW SUPPLIED SECTION

GENTAK® Gentamicin sulfate ophthalmic ointment USP, 0.3% is supplied in 3.5 g tube, box of one.

(NDC 17478-827-35)

STORAGE AND HANDLING SECTION

STORAGE: Store at 2° to 30°C (36° to 86°F).

PREMIERProRx®
Manufactured by: Akorn, Inc.
Lake Forest, IL 60045

PremierProRx® is a registered trademark of Premier, Inc., used under license.

PGKO00N
Rev. 10/15

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Container Label:

NDC 17478-827-35

GENTAK®

brand of Gentamicin Sulfate

Ophthalmic Ointment USP, 0.3%

(equivalent to 3 mg gentamicin per gram)

Net Wt 3.5 g (1/8 oz) Sterile

Rx only

Principal Display Panel Text for Container Label
Principal Display Panel Text for Container Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Carton Label:

NDC 17478-827-35

GENTAK®

Brand of Gentamicin Sulfate Ophthalmic Ointment USP, 0.3%

(equivalent to 3 mg gentamicin per gram)

Sterile

Net Wt 3.5 g (1/8 oz.)

Rx only Premier Logo

Principal Display Panel Text for Carton Label
Principal Display Panel Text for Carton Label

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
17478-827-35GM - Gram17478-8272a6ae310-4462-41f1-9e07-78f38971d33612014-04-03

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
Gentamicin SulfateACTIVE INGREDIENT8X7386QRLV1
GentamicinACTIVE MOIETYT6Z9V48IKG1
Gentamicin SulfateINACTIVE INGREDIENT8X7386QRLV1
MethylparabenINACTIVE INGREDIENTA2I8C7HI9T1
Mineral OilINACTIVE INGREDIENTT5L8T28FGP1
PetrolatumINACTIVE INGREDIENT4T6H12BN9U1
PropylparabenINACTIVE INGREDIENTZ8IX2SC1OH1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
17478-82717478-827-35

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 195 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
MethylparabenMETHYLPARABENA2I8C7HI9TSUSPENSION / ORAL388 mgExact identifier — unii candidate
79 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TOINTMENT / OPHTHALMIC0.05 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHTABLET / ORAL0.2 mgExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHSPRAY / TOPICAL0.8 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TENEMA / RECTAL0.18 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TINJECTION / PERIDURAL1 mgExact identifier — unii candidate
79 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TELIXIR / ORAL800 mgExact identifier — unii candidate
79 equally ranked IID candidates
Mineral OilMINERAL OILT5L8T28FGPTABLET, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
30 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TINJECTION / INTRAMUSCULAR95 mgExact identifier — unii candidate
79 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TDROPS / ORAL1 mg/1mlExact identifier — unii candidate
79 equally ranked IID candidates
Mineral OilMINERAL OILT5L8T28FGPTABLET, CHEWABLE / ORAL6 mgExact identifier — unii candidate
30 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TGEL / VAGINAL8 mgExact identifier — unii candidate
79 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHINJECTION / INTRALESIONAL0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS0.8 mgExact identifier — unii candidate
68 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TSOLUTION/ DROPS / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHDROPS / OPHTHALMIC0.01 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHSOLUTION/ DROPS / OPHTHALMIC0.01 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHINJECTION, SOLUTION / INTRAVENOUS5 mgExact identifier — unii candidate
68 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS15 mgExact identifier — unii candidate
79 equally ranked IID candidates
Mineral OilMINERAL OILT5L8T28FGPCAPSULE, EXTENDED RELEASE / ORAL120 mgExact identifier — unii candidate
30 equally ranked IID candidates
Mineral OilMINERAL OILT5L8T28FGPCREAM / VAGINAL402 mgExact identifier — unii candidate
30 equally ranked IID candidates
Mineral OilMINERAL OILT5L8T28FGPTABLET, FILM COATED / ORALNAExact identifier — unii candidate
30 equally ranked IID candidates
Mineral OilMINERAL OILT5L8T28FGPTABLET, DELAYED RELEASE / ORAL5.67 mgExact identifier — unii candidate
30 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHSUSPENSION / AURICULAR (OTIC)NAExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHPASTE, DENTIFRICE / DENTALNAExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHTABLET, COATED / ORAL0.8 mgExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHSPRAY / NASAL0.2 mgExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHENEMA / RECTAL0.02 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TPOWDER, FOR SOLUTION / ORAL126 mgExact identifier — unii candidate
79 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHINJECTION / PARENTERAL2 mgExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHTABLET, CHEWABLE / ORAL0.14 mgExact identifier — unii candidate
68 equally ranked IID candidates
PetrolatumPETROLATUM4T6H12BN9UEMULSION / TOPICAL7.8 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
Mineral OilMINERAL OILT5L8T28FGPCAPSULE / ORAL120 mgExact identifier — unii candidate
30 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHDROPS / AURICULAR (OTIC)NAExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHSOLUTION / INTRAVENOUS0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TINJECTION / INTRALESIONAL0.15 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
Mineral OilMINERAL OILT5L8T28FGPFILM / TRANSDERMAL11.42 mgExact identifier — unii candidate
30 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TTABLET, EXTENDED RELEASE / ORAL0.17 mgExact identifier — unii candidate
79 equally ranked IID candidates
Mineral OilMINERAL OILT5L8T28FGPDROPS / ORALNAExact identifier — unii candidate
30 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHSOLUTION, CONCENTRATE / ORAL0.2 mg/1mlExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHINJECTION, SUSPENSION / INTRAMUSCULAR0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TSOLUTION / ORAL346 mgExact identifier — unii candidate
79 equally ranked IID candidates
PetrolatumPETROLATUM4T6H12BN9UTABLET / ORAL3.5 mgExact identifier — unii candidate
18 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHSYRUP / ORAL40 mgExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHCREAM, AUGMENTED / TOPICAL2 mgExact identifier — unii candidate
68 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TDROPS / AURICULAR (OTIC)0.01 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
Mineral OilMINERAL OILT5L8T28FGPGEL / TOPICAL2.5 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHSUSPENSION / ORAL64 mgExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHINJECTION / INTRAVENOUS6 mgExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHCONCENTRATE / ORAL2.5 mg/5mlExact identifier — unii candidate
68 equally ranked IID candidates
Mineral OilMINERAL OILT5L8T28FGPOINTMENT / TOPICAL9938 mgExact identifier — unii candidate
30 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHPOWDER, FOR SUSPENSION / ORAL8 mgExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHSOLUTION / RECTAL0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
PetrolatumPETROLATUM4T6H12BN9UCREAM, AUGMENTED / TOPICAL26 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHSOLUTION / RESPIRATORY (INHALATION)0.01 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TPASTE, DENTIFRICE / DENTAL0.05 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHSYSTEM / TOPICAL21 mgExact identifier — unii candidate
68 equally ranked IID candidates
PropylparabenPROPYLPARABENZ8IX2SC1OHLIQUID / TOPICAL0.1 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
PetrolatumPETROLATUM4T6H12BN9UOINTMENT / VAGINAL4084 mgExact identifier — unii candidate
18 equally ranked IID candidates
Mineral OilMINERAL OILT5L8T28FGPSUSPENSION / AURICULAR (OTIC)0.5 %w/vExact identifier — unii candidate
30 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A064093-001GENTAMICIN SULFATEGENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-31

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-3184e616aacf4f…
2026-08-18 06:07:402026-07A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-31caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-31011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-3131067a03dcf5…
2025-08-23 18:47 UTC2025-08A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-316a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-31fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-31b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-3103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-312680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-315bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-31d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-31d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-3179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-31301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-311e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-318072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-315c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-315d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-314b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-3174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-31bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-31782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-3187673890dc5c…
2021-03-12 10:30 UTC2021-03A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-315aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-318869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-31c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-313f01610625f2…
2019-09-15 20:21 UTC2019-09A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-31b00525d2431f…
2019-07-19 19:46 UTC2019-07A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-31ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-316a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-311c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-31ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-31a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-319b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-31a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-313f0d92c62455…
2023-05-13 08:27 UTC2023-05A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMIC1995-08-31053a50430f4f…
2023-01-26 05:58 UTC2023-01A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-313bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-313a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064093-001GENTAMICIN SULFATEEQ 0.3% BASEOINTMENT / OPHTHALMICATRS1995-08-31f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064093-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064093-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064093-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064093-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064093-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064093-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064093-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A064093-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064093-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064093-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064093-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A064093-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A064093-001AT1ea99ee380514…
2023-01-26 05:58 UTC2023-01A064093-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064093-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064093-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A064093-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A064093-001AT1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
97fb96b0-c3c7-4fd2-930f-8f00b09e99ee561cf436-74b8-452c-9fd2-e42f859c87dd2022-05-20Warnings, Adverse reactionsExact identifier
spl set id: 561cf436-74b8-452c-9fd2-e42f859c87dd

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.